董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sara M. Bonstein | 女 | Chair of the Board | 46 | 7.03万美元 | 10.46 | 2026-01-06 |
| Rene Russo | 女 | President, Chief Executive Officer and Director | 51 | 645.15万美元 | 32.54 | 2026-01-06 |
| Yuan Xu | 女 | Director | 59 | 5.96万美元 | 7.78 | 2026-01-06 |
| James Shannon | 男 | Director | 69 | 6.24万美元 | 7.00 | 2026-01-06 |
| Daniel Curran | 男 | Director | 59 | 6.36万美元 | 2.50 | 2026-01-06 |
| Christina Rossi | 女 | Director | 51 | 6.86万美元 | 10.46 | 2026-01-06 |
| Aoife Brennan | 女 | Director | 50 | 6.31万美元 | 1.67 | 2026-01-06 |
| Robert Ross | 男 | Director | 51 | 6.07万美元 | 6.46 | 2026-01-06 |
| Akintunde Bello | -- | Director | -- | 4.63万美元 | 未持股 | 2026-01-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rene Russo | 女 | President, Chief Executive Officer and Director | 51 | 645.15万美元 | 32.54 | 2026-01-06 |
| Christopher Frankenfield | 男 | Chief Financial and Operating Officer | 43 | 322.93万美元 | 2.48 | 2026-01-06 |
| Katarina Luptakova | 女 | Chief Medical Officer | 49 | 219.72万美元 | 3.33 | 2026-01-06 |
| Kevin Brennan | 男 | Senior Vice President, Finance and Accounting | 55 | 未披露 | 未持股 | 2026-01-06 |
董事简历
中英对照 | 中文 | 英文- Sara M. Bonstein
-
Sara M. Bonstein于2014年3月加入Advaxis，担任高级副总裁兼首席财务官。Bonstein女士拥有十年的生命科学行业礼来制药厂（Eli Lilly & Company）、英克隆系统公司（ImClone Systems）和强生公司（Johnson & Johnson）担任财务领导职位的工作经验。在礼来制药厂任职期间，Bonstein女士是六西格玛冠军和黑带，领导了多个有关临床研究、项目管理、财务、制造和商业销售的项目。担任六个西格玛职位前，Bonstein女士担任过英克隆公司（ImClone）的职责递增的多个职位，该公司于2008年被礼来制药厂收购，包括财务部总监，她在该公司领导了潜伏期、临床与制造研发的所有预算与预测工作，涵盖10多个单克抗体癌症疗法，包括治疗癌症的爱必妥，其年销售额达15亿美元。加入英克隆公司前，Bonstein女士是强生公司（Johnson & Johnson）奥斯麦克尼尔制药厂（Ortho McNeil Pharmaceuticals）与奥多生物技术公司（Ortho Biotech）的财务分析师，她在该公司负责大约11亿美元药品销售额的毛利到净利的分析和计算。Bonstein女士2004年毕业于强生公司的财务领导力发展课程。她在新泽西学院（The College of New Jersey）获得金融学的理学学士学位，在莱德大学（Rider University）获得工商管理硕士学位。
Sara M. Bonstein,has served on board of directors since August 2021. Ms. Bonstein has more than two decades of operational and financial leadership in the life sciences industry and has served as chief financial officer of Insmed, Inc., or Insmed, a biopharmaceutical company, since January 2020, where she is responsible for Insmed's key financial functions, including accounting, financial planning and analysis, procurement, and investor relations. Prior to joining Insmed, she served as chief financial officer and chief operating officer of OncoSec Medical Incorporated, a biotechnology company, from May 2018 to January 2020 and as the chief financial officer at Advaxis, Inc., or Advaxis, a biotechnology company, from February 2014 to April 2018. In these roles, Ms. Bonstein has led multiple capital markets and licensing transactions, while establishing strong financial controls, streamlined business operations, and building high performing teams. Prior to Advaxis, Ms. Bonstein served in various finance roles of increasing responsibility, including at Eli Lilly & Company and Johnson & Johnson, or J&J. Ms. Bonstein currently serves as a member of the board of directors of scPharmaceuticals Inc., a public pharmaceutical company. She holds a B.S. in finance from The College of New Jersey and an M.B.A. from Rider University. - Sara M. Bonstein于2014年3月加入Advaxis，担任高级副总裁兼首席财务官。Bonstein女士拥有十年的生命科学行业礼来制药厂（Eli Lilly & Company）、英克隆系统公司（ImClone Systems）和强生公司（Johnson & Johnson）担任财务领导职位的工作经验。在礼来制药厂任职期间，Bonstein女士是六西格玛冠军和黑带，领导了多个有关临床研究、项目管理、财务、制造和商业销售的项目。担任六个西格玛职位前，Bonstein女士担任过英克隆公司（ImClone）的职责递增的多个职位，该公司于2008年被礼来制药厂收购，包括财务部总监，她在该公司领导了潜伏期、临床与制造研发的所有预算与预测工作，涵盖10多个单克抗体癌症疗法，包括治疗癌症的爱必妥，其年销售额达15亿美元。加入英克隆公司前，Bonstein女士是强生公司（Johnson & Johnson）奥斯麦克尼尔制药厂（Ortho McNeil Pharmaceuticals）与奥多生物技术公司（Ortho Biotech）的财务分析师，她在该公司负责大约11亿美元药品销售额的毛利到净利的分析和计算。Bonstein女士2004年毕业于强生公司的财务领导力发展课程。她在新泽西学院（The College of New Jersey）获得金融学的理学学士学位，在莱德大学（Rider University）获得工商管理硕士学位。
- Sara M. Bonstein,has served on board of directors since August 2021. Ms. Bonstein has more than two decades of operational and financial leadership in the life sciences industry and has served as chief financial officer of Insmed, Inc., or Insmed, a biopharmaceutical company, since January 2020, where she is responsible for Insmed's key financial functions, including accounting, financial planning and analysis, procurement, and investor relations. Prior to joining Insmed, she served as chief financial officer and chief operating officer of OncoSec Medical Incorporated, a biotechnology company, from May 2018 to January 2020 and as the chief financial officer at Advaxis, Inc., or Advaxis, a biotechnology company, from February 2014 to April 2018. In these roles, Ms. Bonstein has led multiple capital markets and licensing transactions, while establishing strong financial controls, streamlined business operations, and building high performing teams. Prior to Advaxis, Ms. Bonstein served in various finance roles of increasing responsibility, including at Eli Lilly & Company and Johnson & Johnson, or J&J. Ms. Bonstein currently serves as a member of the board of directors of scPharmaceuticals Inc., a public pharmaceutical company. She holds a B.S. in finance from The College of New Jersey and an M.B.A. from Rider University.
- Rene Russo
-
Rene Russo自2016年4月起担任我们的董事会成员，并于2016年4月至2018年11月担任Arsanis的总裁兼首席执行官。Russo博士还于2015年7月至2016年4月担任Arsanis的首席发展官。自2019年5月起，Russo博士担任Akrevia Therapeutics，LLC（一家私人控股的生物制药公司，专注于开发免疫肿瘤疗法）的首席执行官。在此之前，Russo博士从2003年到2015年5月被默克收购，在CubistPharmaceuticals，Inc.担任了11年多的各种职务，该公司是一家公共制药开发公司，专注于传染病疗法的开发和商业化，最近被默克收购为其全球医疗事务Vice President。从1999年到2004年，她在百时美施贵宝公司（Bristol-Myers Squibb）担任越来越重要的职务，在那里她开始了她的行业职业生涯，担任工业制药传染病博士后。在加入生物技术行业之前，Russo博士在Robert Wood Johnson University Hospital和Princeton Hospital担任临床职位。Russo医生拿到了她的药以及Rutgers University的B.S.。
Rene Russo,has served as chief executive officer and as a member of board of directors since May 2019 and served as Xilio Therapeutics, Inc. president from May 2021 to August 2022 and since September 2023. Dr. Russo served as entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, from November 2018 to May 2019. Prior to that, she served as president and chief executive officer of Arsanis, Inc., or Arsanis, a biopharmaceutical company, from May 2016 to December 2018, and as its chief development officer from June 2015 to May 2016. Prior to joining Arsanis, Dr. Russo served in various roles of increasing responsibility over an 11-year period, culminating in her serving as vice president, global medical affairs, at Cubist Pharmaceuticals, Inc., or Cubist, a pharmaceutical development company, focused on the development and commercialization of infectious disease therapeutics, from 2004 until its acquisition by Merck Research Laboratories, a healthcare company, in May 015. Prior to Cubist, Dr. Russo held R&D roles at Bristol-Myers Squibb Company from 1999 to 2004, where she contributed to the successful development and global commercialization of multiple therapeutics. Dr. Russo served as chair of the board of directors of Invivyd, Inc. (formerly, Adagio Therapeutics, Inc.), a biotechnology company that she co-founded, from July 2020 to June 2022. Additionally, she served as a member of the board of directors of Arsanis from May 2016 to March 2019 and, following its merger with X4 Pharmaceuticals, Inc., or X4 Pharmaceuticals, served as a member of the board of directors of X4 Pharmaceuticals from March 2019 to November 2021. Dr. Russo currently serves on the board of directors of PRxCision, Inc. a private healthcare technology company, and the supervisory board of Leyden Laboratories B.V., a private biopharmaceutical company. Prior to joining the biotechnology industry, Dr. Russo held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital. Dr. Russo received her Pharm.D. and B.S. from Rutgers University and completed a post-doctoral fellowship in infectious diseases with Bristol-Myers Squibb. - Rene Russo自2016年4月起担任我们的董事会成员，并于2016年4月至2018年11月担任Arsanis的总裁兼首席执行官。Russo博士还于2015年7月至2016年4月担任Arsanis的首席发展官。自2019年5月起，Russo博士担任Akrevia Therapeutics，LLC（一家私人控股的生物制药公司，专注于开发免疫肿瘤疗法）的首席执行官。在此之前，Russo博士从2003年到2015年5月被默克收购，在CubistPharmaceuticals，Inc.担任了11年多的各种职务，该公司是一家公共制药开发公司，专注于传染病疗法的开发和商业化，最近被默克收购为其全球医疗事务Vice President。从1999年到2004年，她在百时美施贵宝公司（Bristol-Myers Squibb）担任越来越重要的职务，在那里她开始了她的行业职业生涯，担任工业制药传染病博士后。在加入生物技术行业之前，Russo博士在Robert Wood Johnson University Hospital和Princeton Hospital担任临床职位。Russo医生拿到了她的药以及Rutgers University的B.S.。
- Rene Russo,has served as chief executive officer and as a member of board of directors since May 2019 and served as Xilio Therapeutics, Inc. president from May 2021 to August 2022 and since September 2023. Dr. Russo served as entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, from November 2018 to May 2019. Prior to that, she served as president and chief executive officer of Arsanis, Inc., or Arsanis, a biopharmaceutical company, from May 2016 to December 2018, and as its chief development officer from June 2015 to May 2016. Prior to joining Arsanis, Dr. Russo served in various roles of increasing responsibility over an 11-year period, culminating in her serving as vice president, global medical affairs, at Cubist Pharmaceuticals, Inc., or Cubist, a pharmaceutical development company, focused on the development and commercialization of infectious disease therapeutics, from 2004 until its acquisition by Merck Research Laboratories, a healthcare company, in May 015. Prior to Cubist, Dr. Russo held R&D roles at Bristol-Myers Squibb Company from 1999 to 2004, where she contributed to the successful development and global commercialization of multiple therapeutics. Dr. Russo served as chair of the board of directors of Invivyd, Inc. (formerly, Adagio Therapeutics, Inc.), a biotechnology company that she co-founded, from July 2020 to June 2022. Additionally, she served as a member of the board of directors of Arsanis from May 2016 to March 2019 and, following its merger with X4 Pharmaceuticals, Inc., or X4 Pharmaceuticals, served as a member of the board of directors of X4 Pharmaceuticals from March 2019 to November 2021. Dr. Russo currently serves on the board of directors of PRxCision, Inc. a private healthcare technology company, and the supervisory board of Leyden Laboratories B.V., a private biopharmaceutical company. Prior to joining the biotechnology industry, Dr. Russo held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital. Dr. Russo received her Pharm.D. and B.S. from Rutgers University and completed a post-doctoral fellowship in infectious diseases with Bristol-Myers Squibb.
- Yuan Xu
-
Yuan Xu自2018年3月起担任我们的首席执行官兼董事。在加入我们之前，徐博士于2015年8月至2017年8月在默克担任高级副总裁，领导生物制剂和疫苗的发现，开发和商业化团队。在默克之前，徐博士于2014年3月至2015年8月担任吉利德生物制剂Vice President兼网站负责人，此前曾在诺华、安进、Chiron、葛兰素史克和Genentech任职。徐博士在南京大学获得生物化学学士学位，在马里兰大学获得生物化学博士学位。徐博士还在加州大学（University of California）完成了病毒学和基因治疗的学位后培训。
Yuan Xu has served as our chief executive officer and as a director since March 2018. Before joining us, Dr. Xu was Senior Vice President at Merck from August 2015 to August 2017 where she led teams in biologics and vaccines discovery, development and commercialization. Prior to Merck, Dr. Xu served as a Vice President of Biologics and Site Head at Gilead from March 2014 to August 2015 and previously held positions at Novartis, Amgen, Chiron, GlaxoSmithKline and Genentech. Dr. Xu received a B.S. in biochemistry from Nanjing University and a Ph.D. in biochemistry from the University of Maryland. Dr. Xu also completed her post-degree training in virology and gene therapy at the University of California. - Yuan Xu自2018年3月起担任我们的首席执行官兼董事。在加入我们之前，徐博士于2015年8月至2017年8月在默克担任高级副总裁，领导生物制剂和疫苗的发现，开发和商业化团队。在默克之前，徐博士于2014年3月至2015年8月担任吉利德生物制剂Vice President兼网站负责人，此前曾在诺华、安进、Chiron、葛兰素史克和Genentech任职。徐博士在南京大学获得生物化学学士学位，在马里兰大学获得生物化学博士学位。徐博士还在加州大学（University of California）完成了病毒学和基因治疗的学位后培训。
- Yuan Xu has served as our chief executive officer and as a director since March 2018. Before joining us, Dr. Xu was Senior Vice President at Merck from August 2015 to August 2017 where she led teams in biologics and vaccines discovery, development and commercialization. Prior to Merck, Dr. Xu served as a Vice President of Biologics and Site Head at Gilead from March 2014 to August 2015 and previously held positions at Novartis, Amgen, Chiron, GlaxoSmithKline and Genentech. Dr. Xu received a B.S. in biochemistry from Nanjing University and a Ph.D. in biochemistry from the University of Maryland. Dr. Xu also completed her post-degree training in virology and gene therapy at the University of California.
- James Shannon
-
James Shannon目前担任Mannkind Corporation（一家专注于糖尿病治疗的公共生物制药公司）的董事会主席，并担任ProQR Therapeutics NV（一家公共生物技术公司）的董事会主席。从2012年5月到2015年3月，他曾担任GlaxoSmithKline GSK公司（公共生物制药公司）的首席医疗官，在那里他曾负责患者安全、一般医疗治理、医疗道德和诚信事务，医疗信息以及与正在开发或市场上的任何GSK药物有关的涉及人体受试者的调查。在此之前，Shannon博士在Novartis（一家上市制药公司）工作了十多年。在公司的最后一个职位上，作为制药开发的全球主管，他负责Novartis&8217；的所有开发活动，从临床前到4期，并监督大约40亿美元的年度开发预算。Shannon博士在北爱尔兰贝尔法斯特皇后大学（Queen&8217；s University）获得科学和医学学位。他也担任Kyowa Kirin（NA）（私人生物制药公司和Kyowa Kirin的子公司）的董事会主席，以及Immodulon Therapeutics Limited（私人生物制药公司）、Leyden Labs（私人生物制药公司）和MyTomorrows的董事会成员，一个基于健康的私人平台，与药物开发商合作，为已用尽所有其他选择的患者提供早期治疗。
James Shannon has served on Board since June 2016 and has been Chair of Scientific Advisory Board since 2020 and was elected Chair of Board in May 2024. Dr. Shannon has had an extensive career in drug development and pharma. From 2012 until his retirement in 2015, he was Chief Medical Officer at GlaxoSmithKline. Prior to that he was Global Head of Pharma Development at Novartis and Senior Vice President, Clinical Development at Sterling Winthrop Pharmaceuticals. He previoly held board positions at several companies including Biotie, Circassia, Crucell, Endocyte and Cerimon Pharmaceuticals. More recently Dr. Shannon also served on the boards of Immodulon Therapeutics Limited, myTomorrows, and Horizon Therapeutics. Dr. Shannon currently serves as chairman of the boards at MannKind Corp., a public biopharmaceutical company, and Kyowa Kirin NA, a private biopharmaceutical company and subsidiary of Kyowa Kirin, and holds board positions at Xilio Therapeutics, a public clinical stage biotechnology company, and Leyden Laboratories. He received his undergraduate and postgraduate degrees at Queen's University of Belfast and is a member of the Royal College of Physicians. - James Shannon目前担任Mannkind Corporation（一家专注于糖尿病治疗的公共生物制药公司）的董事会主席，并担任ProQR Therapeutics NV（一家公共生物技术公司）的董事会主席。从2012年5月到2015年3月，他曾担任GlaxoSmithKline GSK公司（公共生物制药公司）的首席医疗官，在那里他曾负责患者安全、一般医疗治理、医疗道德和诚信事务，医疗信息以及与正在开发或市场上的任何GSK药物有关的涉及人体受试者的调查。在此之前，Shannon博士在Novartis（一家上市制药公司）工作了十多年。在公司的最后一个职位上，作为制药开发的全球主管，他负责Novartis&8217；的所有开发活动，从临床前到4期，并监督大约40亿美元的年度开发预算。Shannon博士在北爱尔兰贝尔法斯特皇后大学（Queen&8217；s University）获得科学和医学学位。他也担任Kyowa Kirin（NA）（私人生物制药公司和Kyowa Kirin的子公司）的董事会主席，以及Immodulon Therapeutics Limited（私人生物制药公司）、Leyden Labs（私人生物制药公司）和MyTomorrows的董事会成员，一个基于健康的私人平台，与药物开发商合作，为已用尽所有其他选择的患者提供早期治疗。
- James Shannon has served on Board since June 2016 and has been Chair of Scientific Advisory Board since 2020 and was elected Chair of Board in May 2024. Dr. Shannon has had an extensive career in drug development and pharma. From 2012 until his retirement in 2015, he was Chief Medical Officer at GlaxoSmithKline. Prior to that he was Global Head of Pharma Development at Novartis and Senior Vice President, Clinical Development at Sterling Winthrop Pharmaceuticals. He previoly held board positions at several companies including Biotie, Circassia, Crucell, Endocyte and Cerimon Pharmaceuticals. More recently Dr. Shannon also served on the boards of Immodulon Therapeutics Limited, myTomorrows, and Horizon Therapeutics. Dr. Shannon currently serves as chairman of the boards at MannKind Corp., a public biopharmaceutical company, and Kyowa Kirin NA, a private biopharmaceutical company and subsidiary of Kyowa Kirin, and holds board positions at Xilio Therapeutics, a public clinical stage biotechnology company, and Leyden Laboratories. He received his undergraduate and postgraduate degrees at Queen's University of Belfast and is a member of the Royal College of Physicians.
- Daniel Curran
-
Daniel Curran自2020年12月以来一直担任我们的董事会成员。他拥有超过20年的制药经验，涉及战略、业务开发、项目领导和开发角色。自2008年以来，Curran博士在Takeda Pharmaceutical Company Ltd.或Takeda（一家制药公司）担任越来越重要的职位，最近担任高级副总裁和稀有遗传学和血液学治疗区域单元的负责人。任职Takeda公司之前，他曾担任Millennium Pharmaceuticals公司（Takeda公司的全资子公司）的副总裁，负责公司发展（从1999年6月到2008年）。在加入Millennium之前，Curran博士在杜邦默克制药公司（DuPont Merck Pharmaceuticals，一家制药公司）的产品规划和收购部门担任业务开发职位。自2019年以来，Curran博士一直担任私人眼科生物技术公司Stargazer Pharmaceuticals，Inc.的董事会成员。Curran博士在宾夕法尼亚大学医学院获得医学博士学位，在宾夕法尼亚大学沃顿商学院获得工商管理硕士学位，在国王学院获得化学学士学位。
Daniel Curran,has served as a member of board of directors since December 2020. He has more than 20 years of pharmaceutical experience in strategy, business development, project leadership and development roles. Dr. Curran currently serves as a managing partner at Mountainfield Venture Partners, LLC, a company-creation firm, since March 2024. Previously, Dr. Curran held roles of increasing responsibility at Takeda Pharmaceutical Company Ltd., or Takeda, a pharmaceutical company, since 2008, and most recently served as a senior vice president and the head of the rare genetics and hematology therapeutic area unit from January 2019 until December 2023. Prior to Takeda, he served as vice president,corporate development at Millennium Pharmaceuticals, Inc., or Millennium, a wholly owned subsidiary of Takeda, from 1999 to 2008. Prior to Millennium, Dr. Curran held a business development role in the product planning and acquisition group at DuPont Merck Pharmaceuticals, a pharmaceutical company. Dr. Curran previously served on the board of directors of Tome Biosciences, a private biotechnology company. Dr. Curran received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School of the University of Pennsylvania and a B.S. in chemistry from King's College. - Daniel Curran自2020年12月以来一直担任我们的董事会成员。他拥有超过20年的制药经验，涉及战略、业务开发、项目领导和开发角色。自2008年以来，Curran博士在Takeda Pharmaceutical Company Ltd.或Takeda（一家制药公司）担任越来越重要的职位，最近担任高级副总裁和稀有遗传学和血液学治疗区域单元的负责人。任职Takeda公司之前，他曾担任Millennium Pharmaceuticals公司（Takeda公司的全资子公司）的副总裁，负责公司发展（从1999年6月到2008年）。在加入Millennium之前，Curran博士在杜邦默克制药公司（DuPont Merck Pharmaceuticals，一家制药公司）的产品规划和收购部门担任业务开发职位。自2019年以来，Curran博士一直担任私人眼科生物技术公司Stargazer Pharmaceuticals，Inc.的董事会成员。Curran博士在宾夕法尼亚大学医学院获得医学博士学位，在宾夕法尼亚大学沃顿商学院获得工商管理硕士学位，在国王学院获得化学学士学位。
- Daniel Curran,has served as a member of board of directors since December 2020. He has more than 20 years of pharmaceutical experience in strategy, business development, project leadership and development roles. Dr. Curran currently serves as a managing partner at Mountainfield Venture Partners, LLC, a company-creation firm, since March 2024. Previously, Dr. Curran held roles of increasing responsibility at Takeda Pharmaceutical Company Ltd., or Takeda, a pharmaceutical company, since 2008, and most recently served as a senior vice president and the head of the rare genetics and hematology therapeutic area unit from January 2019 until December 2023. Prior to Takeda, he served as vice president,corporate development at Millennium Pharmaceuticals, Inc., or Millennium, a wholly owned subsidiary of Takeda, from 1999 to 2008. Prior to Millennium, Dr. Curran held a business development role in the product planning and acquisition group at DuPont Merck Pharmaceuticals, a pharmaceutical company. Dr. Curran previously served on the board of directors of Tome Biosciences, a private biotechnology company. Dr. Curran received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School of the University of Pennsylvania and a B.S. in chemistry from King's College.
- Christina Rossi
-
Christina Rossi自2021年4月起担任我们的董事会成员。自2018年10月以来，罗西女士一直担任生物制药公司蓝图医药公司的首席商务官。从2016年1月至2018年10月，罗西女士担任赛诺菲健赞（Sanofi Genzyme，一家生物技术公司）北美区多发性硬化症业务部门负责人。此前，Rossi女士于2014年5月至2015年12月担任赛诺菲多发性硬化症销售副总裁，并于2012年6月至2014年5月担任赛诺菲多发性硬化症患者和提供商服务副总裁。在加入赛诺菲之前，Rossi女士在Biogen担任过各种职务，包括Eidetica Biopharma GmbH的商业战略主管，这是Biogen专注于生物仿制药的合资企业，以及Tysabri®；Natalizumab的美国品牌领导者。此外，Rossi女士还在波士顿咨询集团的医疗保健业务部门担任顾问。罗西女士以优异的成绩获得了杜克大学的生物学学士学位和哈佛商学院的工商管理硕士学位。
Christina Rossi,has served as a member of board of directors since April 2021. Ms. Rossi has served as chief operating officer of Blueprint Medicines Corporation, or Blueprint, a biopharmaceutical company, since April 2022, and from October 2018 to April 2022, Ms. Rossi served as chief commercial officer of Blueprint. From January 2016 to October 2018, Ms. Rossi served as the Multiple Sclerosis business unit head, North America, at Sanofi Genzyme, or Sanofi, a biotechnology company. Previously, Ms. Rossi served as vice president, Multiple Sclerosis Sales at Sanofi from May 2014 to December 2015 and vice president, Multiple Sclerosis Patient and Provider Services at Sanofi from June 2012 to May 2014. Prior to joining Sanofi, Ms. Rossi served in various roles at Biogen, including head, commercial strategy for Eidetica Biopharma GmbH, Biogen's biosimilar-focused venture, and U.S. brand leader for TYSABRI (natalizumab). In addition, Ms. Rossi consulted in the healthcare practice at the Boston Consulting Group. Ms. Rossi holds a B.S. in biology, cum laude, from Duke University and an M.B.A. from Harvard Business School. - Christina Rossi自2021年4月起担任我们的董事会成员。自2018年10月以来，罗西女士一直担任生物制药公司蓝图医药公司的首席商务官。从2016年1月至2018年10月，罗西女士担任赛诺菲健赞（Sanofi Genzyme，一家生物技术公司）北美区多发性硬化症业务部门负责人。此前，Rossi女士于2014年5月至2015年12月担任赛诺菲多发性硬化症销售副总裁，并于2012年6月至2014年5月担任赛诺菲多发性硬化症患者和提供商服务副总裁。在加入赛诺菲之前，Rossi女士在Biogen担任过各种职务，包括Eidetica Biopharma GmbH的商业战略主管，这是Biogen专注于生物仿制药的合资企业，以及Tysabri®；Natalizumab的美国品牌领导者。此外，Rossi女士还在波士顿咨询集团的医疗保健业务部门担任顾问。罗西女士以优异的成绩获得了杜克大学的生物学学士学位和哈佛商学院的工商管理硕士学位。
- Christina Rossi,has served as a member of board of directors since April 2021. Ms. Rossi has served as chief operating officer of Blueprint Medicines Corporation, or Blueprint, a biopharmaceutical company, since April 2022, and from October 2018 to April 2022, Ms. Rossi served as chief commercial officer of Blueprint. From January 2016 to October 2018, Ms. Rossi served as the Multiple Sclerosis business unit head, North America, at Sanofi Genzyme, or Sanofi, a biotechnology company. Previously, Ms. Rossi served as vice president, Multiple Sclerosis Sales at Sanofi from May 2014 to December 2015 and vice president, Multiple Sclerosis Patient and Provider Services at Sanofi from June 2012 to May 2014. Prior to joining Sanofi, Ms. Rossi served in various roles at Biogen, including head, commercial strategy for Eidetica Biopharma GmbH, Biogen's biosimilar-focused venture, and U.S. brand leader for TYSABRI (natalizumab). In addition, Ms. Rossi consulted in the healthcare practice at the Boston Consulting Group. Ms. Rossi holds a B.S. in biology, cum laude, from Duke University and an M.B.A. from Harvard Business School.
- Aoife Brennan
-
Aoife Brennan，自2024年6月起担任总裁兼首席执行官和董事会成员。此前，Brennan博士于2018年10月至2024年3月期间担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。在加入Synlogic, Inc.之前，Brennan博士曾在渤健担任副总裁兼罕见病创新部门负责人，负责ALPROLIX、ELOCTATE和SPINRAZA的全球营销批准，以及推进多个早期项目和外部合作。2020年8月至今担任Fibrogen Inc.董事，2024年6月至今担任Xilio Therapeutics董事。Brennan博士还于2018年10月至2024年3月期间担任Synlogic，Inc.的董事，并于2018年9月至2020年4月收购期间担任Ra Pharmaceuticals，Inc.的董事。Brennan博士拥有爱尔兰都柏林三一学院的医学学位，并完成了普通内科和内分泌学的住院医师和研究金培训。她在波士顿的贝斯以色列女执事医疗中心完成了临床研究和新陈代谢方面的博士后培训，并且是哈佛医学院学者临床科学项目的毕业生。
Aoife Brennan,has served as President and Chief Executive Officer and as a member of board of directors since June 2024. Previously, Dr. Brennan served as President and Chief Executive Officer of Synlogic, Inc., a biopharmaceutical company, from October 2018 to March 2024. Prior to joining Synlogic, Inc., Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIX, ELOCTATE and SPINRAZA as well as the advancement of several early-phase programs and external collaborations. She has served as a director of Fibrogen Inc. since August 2020 and as a director of Xilio Therapeutics, Inc. since June 2024. Dr. Brennan also served as a director of Synlogic, Inc. from October 2018 to March 2024, and as a director of Ra Pharmaceutical, Inc. from September 2018 through its acquisition in April 2020. Dr. Brennan holds a medical degree from Trinity College, Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program. - Aoife Brennan，自2024年6月起担任总裁兼首席执行官和董事会成员。此前，Brennan博士于2018年10月至2024年3月期间担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。在加入Synlogic, Inc.之前，Brennan博士曾在渤健担任副总裁兼罕见病创新部门负责人，负责ALPROLIX、ELOCTATE和SPINRAZA的全球营销批准，以及推进多个早期项目和外部合作。2020年8月至今担任Fibrogen Inc.董事，2024年6月至今担任Xilio Therapeutics董事。Brennan博士还于2018年10月至2024年3月期间担任Synlogic，Inc.的董事，并于2018年9月至2020年4月收购期间担任Ra Pharmaceuticals，Inc.的董事。Brennan博士拥有爱尔兰都柏林三一学院的医学学位，并完成了普通内科和内分泌学的住院医师和研究金培训。她在波士顿的贝斯以色列女执事医疗中心完成了临床研究和新陈代谢方面的博士后培训，并且是哈佛医学院学者临床科学项目的毕业生。
- Aoife Brennan,has served as President and Chief Executive Officer and as a member of board of directors since June 2024. Previously, Dr. Brennan served as President and Chief Executive Officer of Synlogic, Inc., a biopharmaceutical company, from October 2018 to March 2024. Prior to joining Synlogic, Inc., Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIX, ELOCTATE and SPINRAZA as well as the advancement of several early-phase programs and external collaborations. She has served as a director of Fibrogen Inc. since August 2020 and as a director of Xilio Therapeutics, Inc. since June 2024. Dr. Brennan also served as a director of Synlogic, Inc. from October 2018 to March 2024, and as a director of Ra Pharmaceutical, Inc. from September 2018 through its acquisition in April 2020. Dr. Brennan holds a medical degree from Trinity College, Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
- Robert Ross
-
罗伯特·罗斯，自2022年6月起担任董事会成员。Ross博士目前自2023年11月起担任Clasp Therapeutics，Inc.（一家私营生物技术公司Clasp）的首席执行官、总裁和董事会成员。在加入Clasp之前，Ross博士曾于2021年4月起担任生物技术公司Surface Oncology, Inc.（Surface Oncology，Inc.）的首席执行官和董事会成员，直至2023年9月被Coherus生物科技生物科学公司收购。罗斯博士还在2016年10月至2021年4月期间担任Surface的首席医疗官。在加入Surface之前，Ross博士曾在bluebird bio，Inc.或bluebird bio担任肿瘤科负责人，更早之前曾担任临床开发和药物警戒高级副总裁以及临床开发副总裁。在加入bluebird bio之前，Ross博士曾在Genentech和Infinity Pharmaceuticals, Inc. Pharmaceuticals，Inc.工作。Ross博士于2003年至2007年期间担任医学肿瘤学研究员和达纳 Farber癌症研究所（DFCI）的教职员工，随后他在DFCI保持临床实践至2015年。罗斯博士目前担任私营生物技术公司Obsidian Therapeutics，Inc.的董事会成员。Ross博士在斯坦福大学获得生物科学学士学位和哲学学士学位，在哈佛医学院获得医学硕士学位，在哥伦比亚大学内科医生和外科医生学院获得医学博士学位。他在加州大学旧金山分校完成了内科住院医师培训。
Robert Ross,has served as a member of board of directors since June 2022. Dr. Ross currently serves as chief executive officer, president and a member of the board of directors of Clasp Therapeutics, Inc., or Clasp, a private biotechnology company, since November 2023. Prior to Clasp, Dr. Ross served as chief executive officer and a member of the board of directors of Surface Oncology, Inc., or Surface, a biotechnology company, from April 2021 until its acquisition by Coherus Biosciences, Inc. in September 2023. Dr. Ross also served as Surface's chief medical officer from October 2016 to April 2021. Before Surface, Dr. Ross served as the head of oncology at bluebird bio, Inc., or bluebird bio, and earlier served in roles as senior vice president of clinical development and pharmacovigilance and vice president of clinical development. Prior to bluebird bio, Dr. Ross worked at Genentech and Infinity Pharmaceuticals, Inc. Dr. Ross was a Fellow in Medical Oncology and a faculty member at the Dana Farber Cancer Institute, or DFCI, from 2003 to 2007, and then he maintained a clinical practice at DFCI until 2015. Dr. Ross currently serves on the board of directors of Obsidian Therapeutics, Inc., a private biotechnology company. Dr. Ross received a B.S. in biological sciences and a B.A. in philosophy from Stanford University, an M.S. in medical science from Harvard Medical School and an M.D. from Columbia University College of Physicians and Surgeons. He completed his residency training in Internal Medicine at the University of California, San Francisco. - 罗伯特·罗斯，自2022年6月起担任董事会成员。Ross博士目前自2023年11月起担任Clasp Therapeutics，Inc.（一家私营生物技术公司Clasp）的首席执行官、总裁和董事会成员。在加入Clasp之前，Ross博士曾于2021年4月起担任生物技术公司Surface Oncology, Inc.（Surface Oncology，Inc.）的首席执行官和董事会成员，直至2023年9月被Coherus生物科技生物科学公司收购。罗斯博士还在2016年10月至2021年4月期间担任Surface的首席医疗官。在加入Surface之前，Ross博士曾在bluebird bio，Inc.或bluebird bio担任肿瘤科负责人，更早之前曾担任临床开发和药物警戒高级副总裁以及临床开发副总裁。在加入bluebird bio之前，Ross博士曾在Genentech和Infinity Pharmaceuticals, Inc. Pharmaceuticals，Inc.工作。Ross博士于2003年至2007年期间担任医学肿瘤学研究员和达纳 Farber癌症研究所（DFCI）的教职员工，随后他在DFCI保持临床实践至2015年。罗斯博士目前担任私营生物技术公司Obsidian Therapeutics，Inc.的董事会成员。Ross博士在斯坦福大学获得生物科学学士学位和哲学学士学位，在哈佛医学院获得医学硕士学位，在哥伦比亚大学内科医生和外科医生学院获得医学博士学位。他在加州大学旧金山分校完成了内科住院医师培训。
- Robert Ross,has served as a member of board of directors since June 2022. Dr. Ross currently serves as chief executive officer, president and a member of the board of directors of Clasp Therapeutics, Inc., or Clasp, a private biotechnology company, since November 2023. Prior to Clasp, Dr. Ross served as chief executive officer and a member of the board of directors of Surface Oncology, Inc., or Surface, a biotechnology company, from April 2021 until its acquisition by Coherus Biosciences, Inc. in September 2023. Dr. Ross also served as Surface's chief medical officer from October 2016 to April 2021. Before Surface, Dr. Ross served as the head of oncology at bluebird bio, Inc., or bluebird bio, and earlier served in roles as senior vice president of clinical development and pharmacovigilance and vice president of clinical development. Prior to bluebird bio, Dr. Ross worked at Genentech and Infinity Pharmaceuticals, Inc. Dr. Ross was a Fellow in Medical Oncology and a faculty member at the Dana Farber Cancer Institute, or DFCI, from 2003 to 2007, and then he maintained a clinical practice at DFCI until 2015. Dr. Ross currently serves on the board of directors of Obsidian Therapeutics, Inc., a private biotechnology company. Dr. Ross received a B.S. in biological sciences and a B.A. in philosophy from Stanford University, an M.S. in medical science from Harvard Medical School and an M.D. from Columbia University College of Physicians and Surgeons. He completed his residency training in Internal Medicine at the University of California, San Francisco.
- Akintunde Bello
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Rene Russo
Rene Russo自2016年4月起担任我们的董事会成员，并于2016年4月至2018年11月担任Arsanis的总裁兼首席执行官。Russo博士还于2015年7月至2016年4月担任Arsanis的首席发展官。自2019年5月起，Russo博士担任Akrevia Therapeutics，LLC（一家私人控股的生物制药公司，专注于开发免疫肿瘤疗法）的首席执行官。在此之前，Russo博士从2003年到2015年5月被默克收购，在CubistPharmaceuticals，Inc.担任了11年多的各种职务，该公司是一家公共制药开发公司，专注于传染病疗法的开发和商业化，最近被默克收购为其全球医疗事务Vice President。从1999年到2004年，她在百时美施贵宝公司（Bristol-Myers Squibb）担任越来越重要的职务，在那里她开始了她的行业职业生涯，担任工业制药传染病博士后。在加入生物技术行业之前，Russo博士在Robert Wood Johnson University Hospital和Princeton Hospital担任临床职位。Russo医生拿到了她的药以及Rutgers University的B.S.。
Rene Russo,has served as chief executive officer and as a member of board of directors since May 2019 and served as Xilio Therapeutics, Inc. president from May 2021 to August 2022 and since September 2023. Dr. Russo served as entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, from November 2018 to May 2019. Prior to that, she served as president and chief executive officer of Arsanis, Inc., or Arsanis, a biopharmaceutical company, from May 2016 to December 2018, and as its chief development officer from June 2015 to May 2016. Prior to joining Arsanis, Dr. Russo served in various roles of increasing responsibility over an 11-year period, culminating in her serving as vice president, global medical affairs, at Cubist Pharmaceuticals, Inc., or Cubist, a pharmaceutical development company, focused on the development and commercialization of infectious disease therapeutics, from 2004 until its acquisition by Merck Research Laboratories, a healthcare company, in May 2015. Prior to Cubist, Dr. Russo held R&D roles at Bristol-Myers Squibb Company from 1999 to 2004, where she contributed to the successful development and global commercialization of multiple therapeutics. Dr. Russo served as chair of the board of directors of Invivyd, Inc. (formerly, Adagio Therapeutics, Inc.), a biotechnology company that she co-founded, from July 2020 to June 2022. Additionally, she served as a member of the board of directors of Arsanis from May 2016 to March 2019 and, following its merger with X4 Pharmaceuticals, Inc., or X4 Pharmaceuticals, served as a member of the board of directors of X4 Pharmaceuticals from March 2019 to November 2021. Dr. Russo currently serves on the board of directors of PRxCision, Inc. a private healthcare technology company, and the supervisory board of Leyden Laboratories B.V., a private biopharmaceutical company. Prior to joining the biotechnology industry, Dr. Russo held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital. Dr. Russo received her Pharm.D. and B.S. from Rutgers University and completed a post-doctoral fellowship in infectious diseases with Bristol-Myers Squibb.- Rene Russo自2016年4月起担任我们的董事会成员，并于2016年4月至2018年11月担任Arsanis的总裁兼首席执行官。Russo博士还于2015年7月至2016年4月担任Arsanis的首席发展官。自2019年5月起，Russo博士担任Akrevia Therapeutics，LLC（一家私人控股的生物制药公司，专注于开发免疫肿瘤疗法）的首席执行官。在此之前，Russo博士从2003年到2015年5月被默克收购，在CubistPharmaceuticals，Inc.担任了11年多的各种职务，该公司是一家公共制药开发公司，专注于传染病疗法的开发和商业化，最近被默克收购为其全球医疗事务Vice President。从1999年到2004年，她在百时美施贵宝公司（Bristol-Myers Squibb）担任越来越重要的职务，在那里她开始了她的行业职业生涯，担任工业制药传染病博士后。在加入生物技术行业之前，Russo博士在Robert Wood Johnson University Hospital和Princeton Hospital担任临床职位。Russo医生拿到了她的药以及Rutgers University的B.S.。
- Rene Russo,has served as chief executive officer and as a member of board of directors since May 2019 and served as Xilio Therapeutics, Inc. president from May 2021 to August 2022 and since September 2023. Dr. Russo served as entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, from November 2018 to May 2019. Prior to that, she served as president and chief executive officer of Arsanis, Inc., or Arsanis, a biopharmaceutical company, from May 2016 to December 2018, and as its chief development officer from June 2015 to May 2016. Prior to joining Arsanis, Dr. Russo served in various roles of increasing responsibility over an 11-year period, culminating in her serving as vice president, global medical affairs, at Cubist Pharmaceuticals, Inc., or Cubist, a pharmaceutical development company, focused on the development and commercialization of infectious disease therapeutics, from 2004 until its acquisition by Merck Research Laboratories, a healthcare company, in May 2015. Prior to Cubist, Dr. Russo held R&D roles at Bristol-Myers Squibb Company from 1999 to 2004, where she contributed to the successful development and global commercialization of multiple therapeutics. Dr. Russo served as chair of the board of directors of Invivyd, Inc. (formerly, Adagio Therapeutics, Inc.), a biotechnology company that she co-founded, from July 2020 to June 2022. Additionally, she served as a member of the board of directors of Arsanis from May 2016 to March 2019 and, following its merger with X4 Pharmaceuticals, Inc., or X4 Pharmaceuticals, served as a member of the board of directors of X4 Pharmaceuticals from March 2019 to November 2021. Dr. Russo currently serves on the board of directors of PRxCision, Inc. a private healthcare technology company, and the supervisory board of Leyden Laboratories B.V., a private biopharmaceutical company. Prior to joining the biotechnology industry, Dr. Russo held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital. Dr. Russo received her Pharm.D. and B.S. from Rutgers University and completed a post-doctoral fellowship in infectious diseases with Bristol-Myers Squibb.
- Christopher Frankenfield
Christopher Frankenfield，自2024年8月起担任首席财务官，自2023年8月起担任首席运营官。Frankenfield先生此前曾于2022年8月至2023年8月担任首席法律和行政官，并于2021年3月至2022年8月担任Xilio Therapeutics，Inc.总法律顾问。在加入Xilio Therapeutics, Inc.之前，Frankenfield先生于2015年8月至2021年3月在蓝图医药公司（Blueprint Medicines Corporation）担任职责不断增加的职务，包括于2019年7月至2021年3月担任公司法律事务副总裁。在Blueprint任职期间，Frankenfield先生负责一系列公司法律活动，包括上市公司报告、资本市场战略和后续股权发行、合作和伙伴关系，以及支持商业产品发布。在加入Blueprint之前，Frankenfield先生是Wilmer Cutler Pickering Hale and Dorr LLP的高级合伙人，他的执业重点是资本市场和战略交易、上市公司报告和公司治理事务。弗兰肯菲尔德先生的职业生涯始于普华永道会计师事务所的咨询业务。他在威廉玛丽学院获得经济学学士学位，在弗吉尼亚大学法学院获得法学博士学位。
Christopher Frankenfield,has served as chief financial officer since August 2024 and chief operating officer since August 2023. Mr. Frankenfield previously served as chief legal and administrative officer from August 2022 to August 2023 and as Xilio Therapeutics, Inc. general counsel from March 2021 to August 2022. Prior to joining Xilio Therapeutics, Inc. , Mr. Frankenfield served in roles of increasing responsibility at Blueprint Medicines Corporation, or Blueprint, from August 2015 to March 2021, including as vice president of corporate legal affairs from July 2019 to March 2021. While at Blueprint, Mr. Frankenfield was responsible for a range of corporate legal activities, including public company reporting, capital markets strategy and follow-on equity offerings, collaborations and partnerships, and supporting commercial product launches. Prior to joining Blueprint, Mr. Frankenfield was a senior associate at Wilmer Cutler Pickering Hale and Dorr LLP, where his practice focused on capital markets and strategic transactions, public company reporting and corporate governance matters. Mr. Frankenfield began his career in the advisory practice at PricewaterhouseCoopers LLP. He received his B.A. in economics from the College of William & Mary and his J.D. from the University of Virginia School of Law.- Christopher Frankenfield，自2024年8月起担任首席财务官，自2023年8月起担任首席运营官。Frankenfield先生此前曾于2022年8月至2023年8月担任首席法律和行政官，并于2021年3月至2022年8月担任Xilio Therapeutics，Inc.总法律顾问。在加入Xilio Therapeutics, Inc.之前，Frankenfield先生于2015年8月至2021年3月在蓝图医药公司（Blueprint Medicines Corporation）担任职责不断增加的职务，包括于2019年7月至2021年3月担任公司法律事务副总裁。在Blueprint任职期间，Frankenfield先生负责一系列公司法律活动，包括上市公司报告、资本市场战略和后续股权发行、合作和伙伴关系，以及支持商业产品发布。在加入Blueprint之前，Frankenfield先生是Wilmer Cutler Pickering Hale and Dorr LLP的高级合伙人，他的执业重点是资本市场和战略交易、上市公司报告和公司治理事务。弗兰肯菲尔德先生的职业生涯始于普华永道会计师事务所的咨询业务。他在威廉玛丽学院获得经济学学士学位，在弗吉尼亚大学法学院获得法学博士学位。
- Christopher Frankenfield,has served as chief financial officer since August 2024 and chief operating officer since August 2023. Mr. Frankenfield previously served as chief legal and administrative officer from August 2022 to August 2023 and as Xilio Therapeutics, Inc. general counsel from March 2021 to August 2022. Prior to joining Xilio Therapeutics, Inc. , Mr. Frankenfield served in roles of increasing responsibility at Blueprint Medicines Corporation, or Blueprint, from August 2015 to March 2021, including as vice president of corporate legal affairs from July 2019 to March 2021. While at Blueprint, Mr. Frankenfield was responsible for a range of corporate legal activities, including public company reporting, capital markets strategy and follow-on equity offerings, collaborations and partnerships, and supporting commercial product launches. Prior to joining Blueprint, Mr. Frankenfield was a senior associate at Wilmer Cutler Pickering Hale and Dorr LLP, where his practice focused on capital markets and strategic transactions, public company reporting and corporate governance matters. Mr. Frankenfield began his career in the advisory practice at PricewaterhouseCoopers LLP. He received his B.A. in economics from the College of William & Mary and his J.D. from the University of Virginia School of Law.
- Katarina Luptakova
Katarina Luptakova，自2023年9月起担任首席医疗官。Luptakova博士此前曾于2022年10月至2023年9月担任医学高级副总裁，并于2021年12月至2022年10月担任临床研究副总裁。Luptakova博士是一位血液学家和肿瘤学家，在临床实践和肿瘤药物开发方面拥有20年的经验。在加入Xilio Therapeutics, Inc.之前，Luptakova博士于2020年4月至2021年10月期间，通过2021年7月被MorphoSys AG收购，在生物制药公司Constellation Pharmaceuticals, Inc.担任临床开发副总裁。在此之前，Luptakova博士于2018年3月至2020年4月在Tesaro, Inc.或制药公司Tesaro担任高级医学总监和临床主任，并于2017年9月至2018年3月担任医学总监。在Tesaro期间，Luptakova博士为多种癌症疗法的成功开发和商业化做出了贡献，其中包括Zejula（niraparib）和blenrep（belantamab mafodotin-blmf）。在加入Tesaro之前，Luptakova博士在Takeda Pharmaceutical Company Limited的全球肿瘤业务部门Takeda Oncology担任医疗事务方面的职责越来越重。在她职业生涯的早期，Luptakova医生是贝斯以色列女执事医疗中心骨髓移植和恶性血液学部门的主治医师。Luptakova博士在斯洛伐克布拉迪斯拉发的夸美纽斯大学医学院获得医学博士学位，并在明爱圣伊丽莎白医疗中心完成了内科住院医师培训，并在波士顿的贝斯以色列女执事医疗中心完成了血液学/肿瘤学临床和研究奖学金。
Katarina Luptakova,has served as chief medical officer since September 2023. Dr. Luptakova previously served as senior vice president, medical, from October 2022 to September 2023 and as vice president, clinical research, from December 2021 to October 2022. Dr. Luptakova is a hematologist and oncologist with 20 years of experience in clinical practice and oncology drug development. Prior to joining Xilio Therapeutics, Inc. , Dr. Luptakova served as vice president, clinical development at Constellation Pharmaceuticals, Inc., a biopharmaceutical company, from April 2020 to October 2021, through its acquisition by MorphoSys AG in July 2021. Prior to that, Dr. Luptakova served as senior medical director and clinical lead at Tesaro, Inc., or Tesaro, a pharmaceutical company, from March 2018 to April 2020, and as medical director from September 2017 to March 2018. While at Tesaro, Dr. Luptakova contributed to the successful development and commercialization of multiple cancer therapies, including Zejula (niraparib) and Blenrep (belantamab mafodotin-blmf). Prior to Tesaro, Dr. Luptakova held roles of increasing responsibility in medical affairs at Takeda Oncology, the global oncology business unit of Takeda Pharmaceutical Company Limited. Earlier in her career, Dr. Luptakova was an attending physician in the Bone Marrow Transplant and Malignant Hematology division at Beth Israel Deaconess Medical Center. Dr. Luptakova received an M.D. from the Comenius University School of Medicine, Bratislava, Slovakia and completed her residency training in Internal Medicine at Caritas St. Elizabeth's Medical Center and a clinical and research fellowship in hematology/oncology at the Beth Israel Deaconess Medical Center in Boston.- Katarina Luptakova，自2023年9月起担任首席医疗官。Luptakova博士此前曾于2022年10月至2023年9月担任医学高级副总裁，并于2021年12月至2022年10月担任临床研究副总裁。Luptakova博士是一位血液学家和肿瘤学家，在临床实践和肿瘤药物开发方面拥有20年的经验。在加入Xilio Therapeutics, Inc.之前，Luptakova博士于2020年4月至2021年10月期间，通过2021年7月被MorphoSys AG收购，在生物制药公司Constellation Pharmaceuticals, Inc.担任临床开发副总裁。在此之前，Luptakova博士于2018年3月至2020年4月在Tesaro, Inc.或制药公司Tesaro担任高级医学总监和临床主任，并于2017年9月至2018年3月担任医学总监。在Tesaro期间，Luptakova博士为多种癌症疗法的成功开发和商业化做出了贡献，其中包括Zejula（niraparib）和blenrep（belantamab mafodotin-blmf）。在加入Tesaro之前，Luptakova博士在Takeda Pharmaceutical Company Limited的全球肿瘤业务部门Takeda Oncology担任医疗事务方面的职责越来越重。在她职业生涯的早期，Luptakova医生是贝斯以色列女执事医疗中心骨髓移植和恶性血液学部门的主治医师。Luptakova博士在斯洛伐克布拉迪斯拉发的夸美纽斯大学医学院获得医学博士学位，并在明爱圣伊丽莎白医疗中心完成了内科住院医师培训，并在波士顿的贝斯以色列女执事医疗中心完成了血液学/肿瘤学临床和研究奖学金。
- Katarina Luptakova,has served as chief medical officer since September 2023. Dr. Luptakova previously served as senior vice president, medical, from October 2022 to September 2023 and as vice president, clinical research, from December 2021 to October 2022. Dr. Luptakova is a hematologist and oncologist with 20 years of experience in clinical practice and oncology drug development. Prior to joining Xilio Therapeutics, Inc. , Dr. Luptakova served as vice president, clinical development at Constellation Pharmaceuticals, Inc., a biopharmaceutical company, from April 2020 to October 2021, through its acquisition by MorphoSys AG in July 2021. Prior to that, Dr. Luptakova served as senior medical director and clinical lead at Tesaro, Inc., or Tesaro, a pharmaceutical company, from March 2018 to April 2020, and as medical director from September 2017 to March 2018. While at Tesaro, Dr. Luptakova contributed to the successful development and commercialization of multiple cancer therapies, including Zejula (niraparib) and Blenrep (belantamab mafodotin-blmf). Prior to Tesaro, Dr. Luptakova held roles of increasing responsibility in medical affairs at Takeda Oncology, the global oncology business unit of Takeda Pharmaceutical Company Limited. Earlier in her career, Dr. Luptakova was an attending physician in the Bone Marrow Transplant and Malignant Hematology division at Beth Israel Deaconess Medical Center. Dr. Luptakova received an M.D. from the Comenius University School of Medicine, Bratislava, Slovakia and completed her residency training in Internal Medicine at Caritas St. Elizabeth's Medical Center and a clinical and research fellowship in hematology/oncology at the Beth Israel Deaconess Medical Center in Boston.
- Kevin Brennan
Kevin Brennan，自2023年3月起担任财务和会计高级副总裁。Brennan先生在生物技术行业拥有超过25年的财务和会计经验。在加入之前，Brennan先生最近于2020年11月至2023年3月在Allena制药有限公司或Allena（一家上市生物制药公司）担任财务副总裁，负责监督Allena的会计和财务运营及战略，以及上市公司报告。从2011年10月到2020年10月，Brennan先生在Allena担任财务和会计职务，职责不断增加。在加入Allena之前，Brennan先生曾在生物技术行业的多家公司担任财务和会计职务。布伦南先生的职业生涯始于毕马威会计师事务所的审计业务，他获得了波士顿学院华莱士·卡罗尔管理学院的会计学士学位。
Kevin Brennan,has served as senior vice president, finance and accounting, since March 2023. Mr. Brennan has more than 25 years of finance and accounting experience within the biotechnology industry. Prior to joining, Mr. Brennan most recently served as vice president of finance at Allena Pharmaceuticals, Inc., or Allena, a public biopharmaceutical company, from November 2020 to March 2023, where he oversaw Allena's accounting and finance operations and strategy, as well as public company reporting. From October 2011 to October 2020, Mr. Brennan held finance and accounting roles of increasing responsibility at Allena. Prior to Allena, Mr. Brennan served in finance and accounting roles at various companies within the biotechnology industry. Mr. Brennan began his career in the audit practice at KPMG LLP, and he received a B.S. in accounting from the Wallace Carroll School of Management at Boston College.- Kevin Brennan，自2023年3月起担任财务和会计高级副总裁。Brennan先生在生物技术行业拥有超过25年的财务和会计经验。在加入之前，Brennan先生最近于2020年11月至2023年3月在Allena制药有限公司或Allena（一家上市生物制药公司）担任财务副总裁，负责监督Allena的会计和财务运营及战略，以及上市公司报告。从2011年10月到2020年10月，Brennan先生在Allena担任财务和会计职务，职责不断增加。在加入Allena之前，Brennan先生曾在生物技术行业的多家公司担任财务和会计职务。布伦南先生的职业生涯始于毕马威会计师事务所的审计业务，他获得了波士顿学院华莱士·卡罗尔管理学院的会计学士学位。
- Kevin Brennan,has served as senior vice president, finance and accounting, since March 2023. Mr. Brennan has more than 25 years of finance and accounting experience within the biotechnology industry. Prior to joining, Mr. Brennan most recently served as vice president of finance at Allena Pharmaceuticals, Inc., or Allena, a public biopharmaceutical company, from November 2020 to March 2023, where he oversaw Allena's accounting and finance operations and strategy, as well as public company reporting. From October 2011 to October 2020, Mr. Brennan held finance and accounting roles of increasing responsibility at Allena. Prior to Allena, Mr. Brennan served in finance and accounting roles at various companies within the biotechnology industry. Mr. Brennan began his career in the audit practice at KPMG LLP, and he received a B.S. in accounting from the Wallace Carroll School of Management at Boston College.